REDUCE-IT: Effect of Icosapent Ethyl on Heart Failure Events in Patients Receiving Statin Therapy

May 15-17, 2021; Virtual
Reduction in CV events seen with fish oil derivative in REDUCE-IT.
Format: Microsoft PowerPoint (.ppt)
File Size: 354 KB
Released: June 25, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), expert commentary on new data in heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 8, 2021 Expired: December 7, 2022

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021

From AHA 2021, new analysis from EMPEROR-Preserved trial of empagliflozin in patients with “true” HFpEF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From AHA 2021, new analysis of TRED-HF trial on detecting early relapse after HF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue